Using IHC, strong positivity (2+, 3+) for the HER1 receptor was found in only 5% of the tumours, for HER2 in 26%, for HER3 in 74%, for HER4 in 51%, and for PTK6 in 59% (Table 1). This evidence concerns the gene ERBB3 and neoplasm.